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We report a case of propofol infusion syndrome (PRIS) in a young female treated for status epilepticus. In this case,
PRIS rapidly evolved to full cardiovascular collapse despite aggressive supportive care in the intensive care unit, as
well as prompt discontinuation of the offending agent. She progressed to refractory cardiac arrest requiring
emergent initiation of venoarterial extracorporeal membrane oxygenation (ECMO) during cardiopulmonary
resuscitation (CPR). She regained a perfusing rhythm after prolonged (>8 hours) asystole, was weaned off ECMO
and eventually all life support, and was discharged to home. We also present a review of the available literature on
the use of ECMO for PRIS.
Keywords: Propofol infusion syndrome; Cardiogenic shock; Extracorporeal membrane oxygenationIntroduction
Propofol infusion, frequently used in the intensive care
setting for sedation or for refractory status epilepticus,
has been associated with a rare, but grave complication:
propofol infusion syndrome (PRIS). We describe a case of
particularly severe PRIS that was successfully resuscitated
with extracorporeal membrane oxygenation (ECMO), des-
pite prolonged evidence of cardiopulmonary arrest (asys-
tole). This case highlights the potential severity of this
syndrome, the benefits of aggressive treatment, which may
include extracorporeal circulation, but also the debilitating
complications associated with ECMO.
Case report
The patient is a 20-year-old Caucasian female with a
past medical history significant only for anemia who
presented to a referring center’s emergency department
(ED) with persistent spinal headache following a normal
spontaneous vaginal delivery managed with epidural an-
algesia. She underwent a blood patch on postpartum day
1, which was repeated on postpartum day 3 without* Correspondence: fmihm@stanford.edu
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in any medium, provided the original work is prelief of her headache. She returned to the ED postpar-
tum day 5 for continued headaches and was admitted
for bed rest and caffeine therapy. On the night of admis-
sion, the patient started seizing (tonic-clonic) and be-
came apneic requiring intubation and intensive care unit
(ICU) admission. The seizures abated before administra-
tion of lorazepam, but she had a second seizure and was
placed on a midazolam and propofol infusion for sed-
ation and seizure control. In consultation with neur-
ology, she was started on phenytoin and valproic acid.
Ceftriaxone and vancomycin were started empirically for
meningitis; both were stopped early, because cultures
remained negative. A magnetic resonance imaging (MRI)
study of her lumbar spine showed a cerebral spinal fluid
(CSF) leak with evidence of CSF anterior and posterior to
the thecal sac from the upper lumbar spine extending
down to the sacrum. A brain MRI demonstrated signs of
intracranial hypotension without evidence of hemorrhage.
Magnetic resonance venography (MRV) of the brain
was negative for venous thrombosis. Neurosurgery was
consulted for possible surgical repair of the CSF leak but
determined that the leak could be managed medically with
bed rest, Trendelenburg positioning, and a larger blood
patch. During the next 12–24 hours, the patient continued
to present seizures as demonstrated by spot electroen-
cephalography (EEG). Her propofol infusion was increasedan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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epileptic burst suppression. The following day, the patient
rapidly developed fluid resistant shock, a severe metabolic
acidosis, acute oliguric kidney failure, an elevated creatine
kinase, and transaminases. Propofol was discontinued
given the concern for possible PRIS; she was resusci-
tated with crystalloid and started on an epinephrine
drip titrated to 150 ng/kg/min to maintain a mean ar-
terial pressure >65 mmHg. She was then emergently
transferred to an academic tertiary referral center for
a higher level of care.
Significant labs at time of transfer included: serum
bicarbonate 10 mmol/L, lactate 11 mg/dL, a creatine kin-
ase (CK) of 341,000 U/L, arterial blood gas (ABG) 7.37/
20/147/11/Base deficit 14 (on pressure control ventilation
(PCV), peak inspiratory pressure of 15 cmH2O, positive
end expiratory pressure of 5 cmH2O, FiO2 50%), white
blood cells count (WBC) 32 × 109/L, AST 3827 U/L,
ALT 789 U/L, alkaline phosphatase 193 U/L, total biliru-
bin 0.6 mg/dL, INR 1.4. Her initial ECG was concerning
for a new onset right bundle branch block with left anter-
ior fascicular block (Figure 1A and B).
During the first 8 hours after transfer, her severe acid-
osis and acute liver failure remained stable and her
lactate level improved, but she became oliguric with
mild hyperkalemia (5.1 mmol/L) and hypocalcemia
(ionized 0.76 mmol/L). Troponins peaked at 15.5 ng/mL
(normal < 0.3 ng/mL) on post-transfer day 1. She was
placed on continuous renal replacement therapy (CRRT).
Cardiology, neurology, and cardiothoracic surgery were
all consulted with early discussions of possibly placing
the patient on extracorporeal membrane oxygenation
(ECMO) or other mechanical cardiac support as a
rescue therapy should she worsen. Propofol having
been discontinued before transfer to our facility, she was
not placed on any other continuous sedation regimen. She
started to awaken and move all extremities upon arrival
with intermittent following of commands, and only re-
quired intermittent boluses of opioids for adequate sed-
ation. A continuous EEG did not show any ongoing
seizure activity. Approximately 8 hours after transfer,
the patient suffered an episode of unstable ventricular
tachycardia (V-tach) requiring three defibrillation at-
tempts (200 Joules biphasic) without CPR (maintained
pulse) resulting in return of a sinus tachycardia with a per-
sistent right bundle branch block (RBBB) and septal lead
ST-segment depression (Figure 1C). She was loaded with
amiodarone and given aggressive calcium/magnesium
replacements. Over the subsequent 6 hours, she con-
tinued to have a very irritable myocardium/conduction
system resulting in atypical intraventricular conduction
delays (IVCDs), progressively widening QRS, atrial flutter/
fibrillation, and an accelerated junctional escape rhythm
(Figure 1D,E,F).At approximately 16:30 that evening, 18 hours after
transfer, the patient suffered another V-tach episode, this
time pulseless, requiring 10 minutes of CPR, 6 (1 mg)
doses of epinephrine, defibrillations, and 100 mg of IV
lidocaine with return of spontaneous circulation. She
remained in an accelerated junctional rhythm/V-tach
with a perfusing blood pressure (101/64 mmHg, heart
rate 135 beats per minute). Because of her continued cir-
culatory and electrophysiologic instability, the decision
was made to place a temporary ventricular assist device
(VAD; Impella, Abiomed®) under fluoroscopic guidance
in the cardiac catheterization laboratory. As she was be-
ing prepared to transfer out of the ICU, she went into
ventricular fibrillation (V-fib). Again, resuscitation at-
tempts were continued with continuous CPR, epineph-
rine, and ventilation. The decision was made to place
her emergently onto ECMO while undergoing active ad-
vanced cardiac life support (ACLS) resuscitation. She was
cannulated at the bedside using a percutaneously placed
right internal jugular venous catheter and a left femoral
arterial catheter for venous-arterial (V-A) ECMO. During
cannulation, the patient’s rhythm degraded into a fine V-
fib and she became asystolic. Cardiopulmonary resuscita-
tion was continued and after being loaded with 10,000
units of heparin, the patient was placed on the ECMO cir-
cuit while still asystolic and remained with minimal car-
diac motion as seen on bedside echocardiography. The
time from the start of her V-fib arrest to ECMO initiation
was 53 minutes with minimal interruptions in CPR and
ongoing boluses of epinephrine, vasopressin, bicarbonate,
and calcium chloride. Postcardiac arrest therapeutic
hypothermia protocol to 32°C for 24 hours was initiated
via the ECMO circuit for neurologic preservation.
At this time, her labs returned and she was found to
have serum potassium of 8.8 mmol/L (nonhemolyzed)
despite ongoing CRRT. Her CK level peaked at 655,200
U/L. She was given additional calcium chloride, bicar-
bonate, insulin, glucose, sodium polystyrene sulfonate
(Kayexalate®), and the CRRT (in continuous veno-venous
hemodiafiltration mode, or CVVHDF) flows were in-
creased. Despite dialyzing with a potassium bath of zero
mEq/L, with blood flow rate of 300 mL/min, pre- and
post-filter flows of 800 mL/h and 400 mL/h respectively
and dialysate flow of 1,200 mL/h, along with ongoing
medical management for the hyperkalemia, her potas-
sium remained >8 mEq/L for the next 6 hours. Because
of a lack of cardiac activity activated clotting times (ACT)
were attempted to be maintained at >200 seconds. Fre-
quent assessments of cardiac activity using bedside trans-
thoracic echocardiography (TTE) confirmed prolonged and
persistent asystole (see Additional file 1). Concern arose for
thrombus formation given prolonged cardiac standstill and
as the patient was requiring escalating doses of heparin to
achieve the target ACT, anticoagulation was switched to
Figure 1 Sequential appearance of ECG over time in V3 lead.
A On admission to our center. Sinus tachycardia with T-wave
inversion (TWI). B Admission + 6 hours. Sinus tachycardia with ST
depression and prolonged QTc. C Admission + 9 hours. Junctional
rhythm with ongoing ST depression/TWI. D Admission + 12 hours.
Same as C. E Admission + 18 hours. Polymorphic wide complex
tachycardia with QRS slurring. F Admission + 24 hours (ECMO starts
minutes after this ECG). Monomorphic ventricular tachycardia with
sinusoidal appearance. G Admission + 3 days, on ECMO. Nonspecific
intraventricular conduction delay. H Admission + 8 days, after
decannulation from ECMO circuit. Sinus tachycardia with now
narrowed QRS complex and T-wave flattening. I Admission +
60 days. Sinus tachycardia.
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like signal” in the left ventricle (LV) concerning for LV
thrombus formation (Figure 2).
In addition to the ongoing efforts to decrease her
serum potassium, we also attempted unsuccessfully to
chemically pace her heart using isoproterenol, epineph-
rine, and dopamine infusions. Transvenous pacing also
was employed without successful electrical capture of
the heart. Because of the continued inability to lower the
potassium with CRRT the patient was transitioned to
intermittent hemodialysis (iHD). During iHD, her potas-
sium finally responded and dropped to 4.5 mEq/L within
1 hour into the dialysis treatment and she regained a
paced rhythm. She regained a rapidly improving pulse
pressure on arterial line tracing as well as evidence of
aortic valve opening on TTE.
After being on ECMO for 5 days, the patient demon-
strated a dramatic recovery of cardiac function by TTE
with an LVEF 35-40% and normal RV function, facilitat-
ing weaning, and removal from the ECMO circuit [1,2].
She was successfully decannulated from the ECMO cir-
cuit to low-dose vasopressors that were rapidly weaned
by day 7. Perfusion to her lower extremities (LE) was
compromised during ECMO with hypothermia and high-
dose pressors, despite the early use of a reperfusion cath-
eter distal to cannulation site (forward limb). Because of
concerns for compartment syndrome in left LE (ECMO
arterial cannulation site), she underwent fasciotomies. Un-
fortunately, she eventually required a left below-the-knee
amputation (BKA) and a left ileofemoral bypass surgery.
She also underwent a brain MRI which showed left frontal
and right occipital ischemic strokes, concerning for em-
bolic events or cerebral hypoperfusion.
Despite her complicated ICU course, she gradually
awoke with significant residual weakness and paralysis in
the left upper extremity. She eventually recovered nor-
mal renal function after 1 month of dialysis requirement
(creatinine 0.5 mg/dL on follow-up), as well as normal
liver function. Her repeat ECGs showed a sinus rhythm
with minimal lateral T-wave abnormalities (Figure 1H
and I). Outpatient echocardiogram showed normal LV
Figure 2 Transthoracic parasternal long axis view performed at bedside during asystole while on ECMO circuit. Note the “smoky
appearance” in the left atrium (LA) and left ventricle (LV) concerning for developing thrombus.
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60%. She had short-term memory deficits and some de-
pression/anxiety from the events but was cognitively in-
tact. During her prolonged hospitalization, she also
suffered from Clostridium difficile colitis and developed
diffuse calcified lesions in her lungs that were felt to be
secondary to amiodarone toxicity. She was transferred
from our hospital to rehabilitation after 84 days of
hospitalization.
Discussion
Propofol (2,6-diisopropylphenol) is a commonly used
sedative and hypnotic drug in the ICU, allowing easily ti-
tratable continuous sedation [3-5]. It has been FDA ap-
proved since 1993 for sedation induction and maintenance
in anesthesia and intensive care. Its short half-life allows
for frequent neurological assessment. Because of the strong
antiepileptic and neuro-protective properties of the
drug, it is frequently used for treatment of refractory
status epilepticus [6-8]. Neuroprotection is thought to be
due to inactivation of gamma-aminobutyric acid (GABA)
receptors, blockade of excitatory neurotransmitters, re-
duction in cerebral oxygen consumption and intracranial
pressure [9].
Although propofol has appealing properties as a first
line drug for sedation, its clinical use has been limited
because of adverse effects. Significant hypotension, espe-
cially in the hemodynamically unstable patient from
both peripheral vasodilation and cardiac depression, hin-
ders its use. Hypertriglyceridemia and associated compli-
cations also are observed in some patients. The clinicaleffect and occurrence of side effects of propofol are gen-
erally dose- and time-dependent [10].
A rare complication, propofol infusion syndrome
(PRIS), was first described in 1992 [11], and the name
PRIS was first used in 1998 [12]. Initially described in chil-
dren [11-13] and in traumatic brain injury [14], it has been
increasingly reported in critically ill adults [15,16], includ-
ing during treatment for refractory status epilepticus.
Propofol infusion syndrome typically presents as severe
rhabdomyolysis, acute kidney injury, hyperkalemia,
metabolic acidosis, and hepatomegaly. Myocardial in-
jury may occur in severe forms, presenting with vari-
ous ECG changes, including Brugada-like pattern and
coved-type ST-segment elevations, severe arrhythmias,
and cardiovascular collapse [17-19]. Occurrence of the
syndrome, as well as its severity, appears to be dose-
dependent, most cases occurring in patients who received
a propofol dose in excess of 5 mg/kg/hr (80 μg/kg/min)
for at least 48 hours [20]. However, as in our case,
the syndrome has been described with short-term,
high doses [21] and long-term, small doses [22]. Add-
itional well-recognized risk factors for its development
include the coadministration of catecholamines or corti-
costeroids [20,23].
As this constellation of signs and symptoms remains
nonspecific and in the absence of a definitive diagnostic
test, PRIS is always a presumed diagnosis and a differen-
tial diagnosis must always be kept in mind. This includes
septic shock with end-organ hypoperfusion, trauma with
crush injuries, ongoing seizures, toxic rhabdomyolysis
(cocaine, amphetamines), severe alcohol withdrawal/
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or severe hypophosphatemia.
The pathophysiology of PRIS is complex. Propofol in-
fusion syndrome has a higher incidence in critically ill pa-
tients compared with healthy patients receiving propofol
for routine anesthesia. Hence, critical illness, most notably
neurologic injury, might act as a priming factor for propofol
(with or without catecholamines and corticosteroids) to
trigger PRIS [20]. The end-organ damage may result
from an imbalance between energy demand and oxygen
utilization. Propofol, by increasing malonylcarnitine, im-
pairs uptake and mitochondrial oxidation of long-chain
free fatty acids (FFAs) in myocardial and skeletal muscle,
resulting in muscle necrosis [24]. Critically ill patients are
particularly dependent on FFAs for energy production,
and the generation of FFAs from peripheral lipolysis is
catecholamine-driven. Propofol also appears to directly
inhibit the respiratory electron transport chain in car-
diac mitochondria, inhibiting utilization of freely diffusing
medium- and short-chain FFAs [25]. The role of catechol-
amines in the syndrome may be related to direct muscle
damage (contraction band necrosis), as seen in other
high-catecholamine states like pheochromocytoma [26]
and stress-induced (Tako-Tsubo) cardiomyopathy [27,28].
Neurologic injury, frequently present in patients suffering
from PRIS, also is known to produce a high-catecholamine
state with associated muscle damage [29]. Finally, a genetic
predisposition of inappropriate fatty acid oxidation (in-
born error) has been hypothesized but remains uncer-
tain [24,30].
Treatment of PRIS first and foremost relies on rapid
recognition of the syndrome and removal of the offending
agent. Otherwise, the treatment is mainly supportive by
the use of inotropic and vasopressive agents, aggressive
electrolyte control, hemodialysis, or hemofiltration. As
mentioned above, severe forms of PRIS with cardiac injur-
ies and arrhythmias have been reported, with various
arrhythmias including asystole [17], as in our case. For
those severe forms of cardiovascular collapse, mechanical
circulatory support, using VADs or ECMO has been
reported. Extra corporeal membrane oxygenation, espe-
cially VA-ECMO as used in this case, can be deployed to
temporarily support end-organ blood flow and oxygen de-
livery using either central or peripheral cannulation [31].
This remains a high-risk procedure, frequently used in
extremis when other treatment modalities have failed,
or when the patient is too unstable to be transferred
to the catheterization laboratory, as in our case. The risk
of complications (mechanical complications of the circuit,
hemorrhage from anticoagulation and consumptive
coagulopathy, vascular trauma induced by large-bore cath-
eters, local thrombosis with limb ischemia and systemic
emboli, sepsis) remains significant despite advances in the
technique [32]. We found three case reports of the use ofECMO for severe PRIS, two in pediatric populations and
one in a young adult [33-35]. To our knowledge, this is
the first case of such prolonged documented asystole with
survival, despite significant complications.
Review and conclusions
Overall reported mortality for PRIS, usually associated
with the cardiac injury, is as high as 64% [17]. The sim-
ultaneous presence of multiple characteristics of the syn-
drome is associated with increased mortality [36],
highlighting the need for education about PRIS and early
recognition and treatment. Repeated case reports of this
devastating complication of a common ICU drug calls
for increased caution and vigilance when using propofol,
especially in patients requiring increasing doses of vaso-
pressors or in cardiac failure as advised by the American
College of Critical Care Medicine [3]. Many centers have
modified protocols of treatment, including refractory
status epilepticus, suggesting propofol should be moved
to second or third-line choice when alternatives exist.
When used, small doses for short periods of time should
be the norm. Frequent monitoring of CK and lactate
levels, as well as clinical awareness needs to be encour-
aged. For severe cases with cardiovascular collapse,
strong consideration should be given to early transfer to
medical centers with capacities for advanced mechanical
circulatory support.
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